RNF114 and ovarian carcinoma: Consistent with the model where nimbolide covalently targets RNF114, these analogs (2 and 3) completely lost their cytotoxic activity [median inhibitory concentration (IC50) > 10 μM] against UWB1 cells (a BRCA1mut ovarian cancer cell line; see more discussion below).